CENTOGENE Studies Third-Quarter 2020 Economical Benefits and Improves Total Year Direction

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (Globe NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage enterprise targeted on unusual disorders that transforms true-environment clinical and genetic information into actionable details for clients, medical professionals, and pharmaceutical businesses, right now furnished an update on its corporate development and noted its money outcomes for the 3 and nine months finished September 30, 2020.

• Revenues increased 212% compared to Q3 2019, driven by the ongoing growth of our COVID-19 screening presenting
• Enhanced 2020 whole-12 months income steerage to additional than €100 million
• Continued advancement of new pharma partnerships, with 12 new deals signed and a robust restoration predicted in 2021
• Growth of industrial COVID-19 screening, which now involves antigen testing
• Introduced leadership changeover and appointment of Dr. Andrin Oswald as Main Govt Officer to help the future stage of the Company’s expansion

Andrin Oswald, M.D., Main Govt Officer at CENTOGENE, reported, “I am excited to have joined CENTOGENE at these an important phase in the Company’s evolution. When I have only been with CENTOGENE for a number of weeks, it is obvious to me that our complete workforce is focused on achieving a prevalent objective of helping exceptional disease individuals all over the world. We believe that our mission has the likely to noticeably minimize the stress of exceptional ailments – and gives an enjoyable value creation option for our stakeholders at the very same time. Leveraging more than 20 yrs of qualified working experience across the lifetime sciences, such as my time at Novartis and the Bill and Melinda Gates Basis, I am hunting ahead to serving to even further scale and accelerate CENTOGENE’s growth as a chief in the rare disease house.”

Richard Stoffelen, Main Financial Officer at CENTOGENE, reported, “During the third quarter, we noticed a important improve in our revenues, 12 months-around-yr, pushed by our capability to leverage our core competency in exact health-related diagnoses to pivot speedily and supply alternatives to aid address the COVID-19 pandemic. As we method the conclude of what has been an unparalleled yr, I would like to thank the whole CENTOGENE group once a lot more for their versatility and unwavering determination.”

A Stable Basis for 2021

CENTOGENE has leveraged its main competency of giving precise clinical diagnoses, as nicely as its infrastructure, to enable protect against more outbreaks of SARS-CoV-2 (COVID-19) during 2020. As portion of this initiative, CENTOGENE has become one of the premier COVID-screening businesses in Europe and developed a revolutionary and major role in furnishing testing products and services at airports. The beneficial money contribution from COVID-19 screening will enable the Company to make strategic investments to additional solidify its main posture in the unusual illness room. The range of Pharma partnership discussions have also continued to raise considering that Q2 2020, positioning CENTOGENE for further progress in 2021.

Even more information on the Company’s Q3 2020 Earnings, like the management’s dialogue and analysis of fiscal situation and effects of functions, can be uncovered by viewing EDGAR on the SEC site at www.sec.gov, as well as the Trader Relations webpage of the Company’s internet site at http://investors.centogene.com.

About CENTOGENE

CENTOGENE engages in analysis and investigation around rare diseases reworking true-planet medical and genetic details into actionable information and facts for people, doctors, and pharmaceutical companies. Our intention is to bring rationality to treatment method selections and to accelerate the improvement of new orphan drugs by employing our substantial unusual disorder expertise, like epidemiological and scientific info, as nicely as innovative biomarkers. CENTOGENE has designed a worldwide proprietary uncommon disease system primarily based on our serious-earth info repository with about 3.6 billion weighted facts details from about 595,000 people representing above 120 diverse international locations as of September 30, 2020.

The Company’s system consists of epidemiologic, phenotypic, and genetic facts that reflects a world wide inhabitants, and also a biobank of these patients’ blood samples. CENTOGENE thinks this signifies the only platform that comprehensively analyzes multi-amount facts to strengthen the knowing of rare hereditary health conditions, which can aid in the identification of patients and improve our pharmaceutical partners’ potential to provide orphan medications to the industry. As of September 30, 2020, the Corporation collaborated with around 40 pharmaceutical partners covering about 45 diverse rare illnesses.

Significant See and Disclaimer

This press launch is made up of statements that represent “forward-on the lookout statements” as that expression is described in the United States Personal Securities Litigation Reform Act of 1995, such as statements that categorical the Company’s views, expectations, beliefs, programs, aims, assumptions, or projections with regards to potential events or long term final results, in distinction with statements that mirror historical info. Examples consist of discussion of our approaches, financing plans, expansion opportunities, and industry expansion. In some circumstances, you can identify these ahead-looking statements by terminology this sort of as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the damaging of these phrases or related expressions. Forward-hunting statements are based on management’s present-day beliefs and assumptions and on details presently offered to the Corporation. Having said that, these forward-seeking statements are not a ensure of our performance, and you really should not area undue reliance on these kinds of statements. Ahead-hunting statements are issue to many challenges, uncertainties, and other variable instances, these as adverse throughout the world economic ailments and ongoing instability and volatility in the throughout the world economic markets, the effects of the COVID-19 pandemic on our company and benefits of functions, achievable adjustments in existing and proposed laws, regulations and govern-psychological insurance policies, pressures from rising levels of competition and consolidation in our industry, the expense and uncertainty of regulatory approval, which include from the U.S. Food items and Drug Administration, our reliance on third events and collaboration associates, including our potential to control expansion and enter into new customer associations, our dependency on the unusual condition field, our capacity to manage intercontinental enlargement, our reliance on critical staff, our reliance on intellectual assets protection, fluctuations of our functioning outcomes owing to the effect of trade costs, or other things. This sort of challenges and uncertainties may possibly trigger the statements to be inaccurate and readers are cautioned not to position undue reliance on these types of statements. Lots of of these dangers are exterior of the Company’s handle and could bring about its true effects to vary materially from all those it believed would happen. The ahead-searching statements involved in this push launch are produced only as of the day hereof. The Enterprise does not undertake, and particularly declines, any obligation to update any these kinds of statements or to publicly announce the results of any revisions to any these statements to reflect long term gatherings or developments, besides as essential by regulation.

For more facts, make sure you refer to the Threat Elements part in our Once-a-year Report for the calendar year ended December 31, 2019, on Form 20-F submitted with the SEC on April 23, 2020, Kind 6-K made up of our economical outcomes for the three months finished March 31, 2020, furnished to the SEC on June 15, 2020, Form 6-K made up of our money effects for the 3 and 9 months ended September 30, 2020, furnished to the SEC on December 16, 2020, and other recent stories and files furnished to or filed with the U.S. Securities and Exchange Fee (SEC). You may perhaps get these files by going to EDGAR on the SEC website at www.sec.gov.

 

Media Speak to: CENTOGENE Sunshine Kim Chief Technique and Trader Relations Officer [email protected]     FTI Consulting Bridie Lawlor O’Boyle +1.917.929.5684 [email protected]